Palvella Therapeutics (NASDAQ:PVLA - Free Report) had its target price hoisted by HC Wainwright from $38.00 to $75.00 in a report published on Friday morning, Marketbeat reports. The firm currently has a buy rating on the stock.
Several other research analysts have also recently issued reports on the stock. Truist Financial assumed coverage on shares of Palvella Therapeutics in a report on Monday, July 21st. They set a "buy" rating and a $56.00 target price on the stock. Canaccord Genuity Group dropped their target price on shares of Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Raymond James Financial set a $54.00 target price on shares of Palvella Therapeutics and gave the stock an "outperform" rating in a report on Tuesday, August 5th. Lifesci Capital assumed coverage on shares of Palvella Therapeutics in a report on Monday, August 4th. They set an "outperform" rating and a $90.00 target price on the stock. Finally, Chardan Capital increased their target price on shares of Palvella Therapeutics from $50.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the company's stock. According to MarketBeat, Palvella Therapeutics has a consensus rating of "Buy" and a consensus target price of $58.50.
Get Our Latest Research Report on Palvella Therapeutics
Palvella Therapeutics Stock Performance
Palvella Therapeutics stock traded up $1.68 during midday trading on Friday, hitting $50.18. 54,588 shares of the company's stock were exchanged, compared to its average volume of 96,658. Palvella Therapeutics has a 12 month low of $11.17 and a 12 month high of $50.71. The firm has a 50-day moving average of $31.41 and a two-hundred day moving average of $25.91. The company has a market cap of $554.99 million, a PE ratio of -4.15 and a beta of -0.01.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.08). As a group, equities analysts expect that Palvella Therapeutics will post -3.69 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. raised its holdings in shares of Palvella Therapeutics by 4.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company's stock worth $16,283,000 after acquiring an additional 32,388 shares during the period. BNP Paribas Financial Markets purchased a new stake in Palvella Therapeutics in the 2nd quarter valued at about $104,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Palvella Therapeutics during the second quarter worth about $85,000. Marshall Wace LLP lifted its position in shares of Palvella Therapeutics by 61.7% during the second quarter. Marshall Wace LLP now owns 49,077 shares of the company's stock worth $1,106,000 after purchasing an additional 18,732 shares in the last quarter. Finally, New York State Common Retirement Fund purchased a new stake in shares of Palvella Therapeutics during the second quarter worth approximately $110,000. Hedge funds and other institutional investors own 40.11% of the company's stock.
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
See Also
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access